Source: International Congress 2016 – Asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Antoine Poskin (Vilvoorde, Belgium), Alain Michils, Antoine Poskin, Jan Van Schoor, Stefaan Vancayzeele, Sandra Gurdain, Muriel Lins. P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients. Eur Respir J 2016; 48: Suppl. 60, 4122

Member's Comments

No comment yet.

Related content which might interest you: Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Efficacy of omalizumab in Polish real-world patients Source: International Congress 2016 – Asthma management Year: 2016 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study Source: International Congress 2016 – Asthma points to ponder Year: 2016 Omalizumab reduces exacerbations and healthcare utilisation in severe allergic asthma patients UK clinical practice - APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Clinical profile and treatment of elderly patients hospitalized for acute exacerbation of asthma . A comparative study Source: International Congress 2014 – Asthma: clinical problems Year: 2014 What are common COPD symptoms in a real-life setting? The German DACCORD registry Source: International Congress 2014 – COPD markers Year: 2014 First clinical trial of a new IgE-adsorber in allergic asthma Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma Year: 2015 Omalizumab add-on therapy reduces exacerbations among responders: A pooled NNT analysis from 5 phase 3 studies Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Evaluating omalizumab persistency of response after long-term therapy (XPORT) Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 The control of asthma in real life: Baseline evaluation of a long-term study Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 Interim analysis of a prospective study investigating oral corticosteroid (OCS) use in omalizumab treated severe allergic asthma patients: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Finding asthmatics suitable for omalizumab therapy in a district hospital Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment? Year: 2013 Pharmacokinetics of tiotropium in asthma patients from three paediatric clinical trials Source: International Congress 2016 – Paediatric asthma: lessons learned from studies with large sample sizes and multi-centre drug studies Year: 2016 Bronchial thermoplasty in patients with very severe asthma: Safety and clinical outcomes Source: International Congress 2016 – Airway stenting and ablation Year: 2016 QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: Results from a predictive modeling study Source: International Congress 2015 – Asthma mechanisms and management Year: 2015 Lung function response to omalizumab in severe allergic asthma patients in UK clinical practice: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014